NCW visits TCS Nashik: What the fact-finding committee will examine and why its report matters beyond this case
Read More Pharma Industry News Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years? Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now. byPallavi MadhirajuApril 18, 2026